$2 Million SBIR direct to phase II award funds therapeutic development and testing at Stingray Therapeutics and TGen

PHOENIX, Ariz. — October 4, 2022 — The Translational Genomics Research Institute, Part of City of Hope, and Stingray Therapeutics, Inc. of Dallas and Houston, Texas today announced a Small Business Innovation Research (SBIR) accelerated direct to phase II award of $2 Million. The NIH award, known as America’s Seed Fund, provides support to early-stage businesses to bring scientific innovations from bench to bedside.Continue reading

MCCCD Governing Board Names Dr. Steven R. Gonzales the System’s Permanent Chancellor

Tempe, Ariz, September 27, 2022 – Tonight, the Maricopa County Community College District (MCCCD) Governing Board voted to appoint Dr. Steven R. Gonzales as MCCCD’s permanent Chancellor. Dr. Gonzales has led the system in an interim capacity since January 25, 2020, when he was appointed by the Governing Board after the departure of former Chancellor, Dr. Maria Harper-Marinick.Continue reading

Dr. Brinton Named AZ Bioscience Researcher of the Year

Photo of Roberta Diaz Brinton, PhD

Roberta Diaz Brinton, PhD

Roberta Diaz Brinton, PhD, director of the University of Arizona Center for Innovation in Brain Science(CIBS) will be honored as the Arizona Bioscience Researcher of the Year by the Arizona Bioindustry Association (AZBio) at the 2022 AZBio Awards event Sept. 28 at the Phoenix Convention Center.

Dr. Brinton is a Regents Professor of Pharmacology with an additional appointment in neurology in the UArizona College of Medicine – Tucson and a member of BIO5 Institute. She returned to her alma mater in 2016 to create CIBS, a hybrid university/biotech research center designed to advance cures for Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and amyotrophic lateral sclerosis, or ALS, through integrated discovery, translational and clinical science. Since its inception, CIBS has received more than $112 million in grants to advance cures for these neurodegenerative diseases.Continue reading

Aqualung Therapeutics Corp. Announces FDA Clearance of Investigational New Drug (IND) Application for ALT-100, a Novel mAb Therapy for the Treatment of Acute Respiratory Distress Syndrome (ARDS)

– Aqualung will continue the P1A Healthy Human Volunteer Trial and complete the trial first half of 2023
– The Phase 2A study (PUERTA) will be initiated in the 2nd half of 2023
– ALT-100 is the first humanized mAb therapy that targets the eNAMPT protein which plays a pivotal role in regulating inflammation and fibrosisContinue reading

Exact Sciences Awards Grants To Federally Qualified Health Centers Focused On Improving Colorectal Cancer Screening Of Vulnerable Populations

MADISON, Wis.Sept. 22, 2022 — Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today awarded $525,000 in grants to eight federally qualified health centers focused on improving colorectal cancer screening rates in vulnerable populations.Continue reading

Vidium Animal Health® SearchLight DNA® Added to Antech Diagnostics® Portfolio of Tests Expanding Veterinarians’ Ability to Diagnose and Treat Cancer in Dogs

PHOENIX—September 22, 2022Vidium Animal Health announced today that it has entered a reseller agreement with Antech Diagnostics to provide SearchLight DNA, the best-in-class genomic diagnostic for cancer in dogs, to Antech’s large North American customer base. Genomic diagnostics in general, and SearchLight DNA in particular, are a key part of expanding the use of personalized medicine in canine patients.
Continue reading

Aqualung Therapeutics Corp. Awarded $4.8M Dollars From National Institute of Health (NIH) To Develop the ALT-100 Monoclonal Antibody for Pulmonary Arterial Hypertension and Inflammatory Bowel Disease

TUCSON, AZ / ACCESSWIRE / September 21, 2022 / Aqualung Therapeutics, an immunotherapeutics biotech company with an anti-inflammatory and anti-fibrosis therapeutic platform for serious unchecked inflammatory and fibrotic disorders, has been awarded two 3-year NIH FAST-TRACK AWARDS [R42DK135208; R42HL160422) to support development of ALT-100, a humanized monoclonal antibody (mAb) therapy for the chronic indications of Pulmonary Arterial Hypertension (PAH) and Inflammatory Bowel Disease (IBD). The ALT-100 mAb targets the inflammation-inducing damage-associated molecular pattern protein eNAMPT, and is currently in Phase 1A human safety trials.

Continue reading

Arizona Alzheimer’s Disease Research Center (ADRC) Development Grant: Request for Proposals

Optional Pre-proposal Deadline: September 30, 2022 Full Application Deadline: October 28, 2022 Anticipated Start Date: July 1, 2023

PURPOSE: The Arizona Alzheimer’s Disease Research Center (ADRC) invites applications for development grant proposal studies to support basic or clinical biomedical, translational, epidemiological, caregiving, educational, or behavioral studies in AD, ADRD or brain aging research. Developmental projects are intended to help establish the basis for applying for further research funding and further development of the applicant’s career in these areas of research.

Continue reading

The Fundación Instituto Valenciano de Oncología Leverages HTG Technology for Breast Cancer Laboratory-Developed Test







TUCSON, Ariz., Sept. 20, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that the Fundación Instituto Valenciano de Oncología, located in Valencia, Spain (IVO), with its partners, the Fundación Pública Andaluza Progreso y Salud (FPS) and the Centro de Investigación Biomédica en Red (CIBER), have developed a laboratory-developed test (LDT) (the MPD Test) for the assessment of breast cancer recurrence based on their use of the HTG EdgeSeq™ technology.Continue reading